Related Experiment Video
Updated: Jun 10, 2026
05:03
Accessing Early Differentiation of Virus-Specific Follicular Helper CD4+ T Cell in Acute LCMV-Infected Mice
Published on: April 26, 2024
B cell acute lymphocytic leukemia in pregnancy
Justin Bottsford-Miller1, Sina Haeri, Arthur M Baker
1Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill School of Medicine, 3010 Old Clinic Building, CB# 7516, Chapel Hill, NC 27599-7516, USA.
Archives of Gynecology and Obstetrics
|August 19, 2010
Summary
Acute lymphocytic leukemia (ALL) during pregnancy is rare but life-threatening. This case study shows multi-agent chemotherapy is feasible for treating pregnant women with ALL, balancing maternal and fetal risks.
Area of Science:
- Hematology
- Oncology
- Maternal-Fetal Medicine
Background:
- Acute lymphocytic leukemia (ALL) is a rare complication during pregnancy.
- Untreated ALL poses significant maternal and fetal risks.
- Chemotherapy for ALL presents a therapeutic dilemma in pregnant patients due to potential teratogenicity.
Observation:
- A case of ALL diagnosed at 24 weeks of gestation is presented.
- The management strategy for this complex case is detailed.
- Literature review on managing ALL in pregnancy was conducted.
Findings:
- Multi-agent chemotherapy was successfully administered to a pregnant patient with ALL.
- The treatment demonstrated feasibility despite maternal-fetal risks.
- This approach offers a viable option for managing ALL during gestation.
Implications:
- This case highlights a feasible management strategy for ALL in pregnancy.
- It suggests that timely chemotherapy can be safely initiated.
- Further research into optimizing chemotherapy regimens for pregnant ALL patients is warranted.
